Neurocrine Stock Jumps 10% After Hours: Revenue Up 41% as Ingrezza Guidance Rises

Neurocrine Biosciences (NASDAQ: NBIX) jumped about 10% in after-hours trading on Monday, November 2, 2026, after the San Diego biotech reported third-quarter revenue up 41% year over year to $1.1 billion, beat earnings estimates by $1.38 a share, and raised full-year guidance for its lead drug Ingrezza. The stock had closed the regular session down 0.51% at $145.35, then climbed toward $160 after the bell as investors reacted to the company's first-ever quarter with more than $1 billion in net product sales.

What happened

Neurocrine reported total third-quarter revenue of $1.123 billion, up 41% from $795 million a year earlier, according to the company's results release distributed by PR Newswire. Earnings of $3.29 a share beat the $1.91 consensus, and revenue beat the roughly $1.04 billion expected. GAAP net income was $206.5 million, close to the $209.5 million recorded a year ago, as the company spent to support three growing products at once.

The headline inside the numbers was Ingrezza, the company's treatment for tardive dyskinesia and chorea associated with Huntington's disease. Ingrezza net product sales rose 17% year over year to $801 million, which Neurocrine attributed to double-digit volume growth, record prescription levels and strong patient persistency. On the strength of that demand, the company raised its full-year 2026 Ingrezza sales guidance to a range of $2.9 billion to $2.925 billion, up from $2.825 billion to $2.875 billion previously.

The key facts, up front

• Revenue: $1.123 billion in Q3 2026, up 41% from $795 million a year earlier.
• Earnings: $3.29 a share, beating the $1.91 consensus by $1.38.
• Ingrezza: $801 million in sales, up 17%; 2026 guidance raised to $2.9-$2.925 billion.
• Crenessity: $211 million in sales, up 115% from $98 million a year earlier.
• Vykat XR: $107 million in sales, a newer product with no year-ago comparison.
• Stock reaction: closed down 0.51% at $145.35, then traded near $160 after hours, up roughly 9-11% in successive snapshots.

Why it's blowing up

The after-hours move was not about one drug carrying the quarter. Crenessity, Neurocrine's treatment for congenital adrenal hyperplasia, more than doubled sales to $211 million, and Vykat XR added $107 million. Together with Ingrezza, the three products pushed net product sales past $1 billion in a single quarter for the first time in the company's history — the milestone management led with in its commentary.

That diversification matters because Neurocrine has long been valued mainly as an Ingrezza story. A quarter in which the lead drug grows 17%, the second product grows 115%, and a third contributes nine figures gives investors a broader revenue base — and the guidance raise signalled management expects Ingrezza momentum to carry through year-end.

The reaction stood out against a difficult tape: the Nasdaq fell 1.07% on Monday as tech and chip stocks sold off for a third straight day, while the Dow rose 0.41%. Neurocrine had drifted down $0.75 in the regular session on above-average volume of about 1.98 million shares. The release reversed that within minutes, with after-hours trackers showing the shares near $160 — up about 9.5% in Kraken's snapshot, with one closing summary putting the move at 10.66%.

What management said comes next

Looking ahead, Neurocrine pointed to continued growth across Ingrezza, Crenessity and Vykat XR in 2027, alongside two clinical readouts investors will watch closely: Phase 3 results for osavampator in major depressive disorder and for direclidine in schizophrenia. Those programmes are not yet revenue, but positive data would extend the same diversification story that powered Monday's reaction.

The next session is not a formality, though. Even after the jump, the shares remain below their 52-week high of $186.12, while the consensus analyst target reported by MarketBeat sits near $201.14. After-hours moves can also fade when regular trading resumes, especially with Tuesday's U.S. midterm elections and Friday's jobs report ahead.

What's next

The immediate test is whether Neurocrine holds its gains when regular trading opens on Tuesday, and whether analysts lift estimates after the beat and guidance raise. The fourth quarter will be judged against the new full-year Ingrezza range, and the 2027 readouts will decide whether the growth story widens further. This article reports what happened and how markets reacted; it is not a recommendation to buy, sell or hold any security.

Sources

• Neurocrine Biosciences Q3 2026 results release via Morningstar / PR Newswire
• Neurocrine Biosciences Q3 2026 results via TradingView
• The Cerbat Gem — Neurocrine beats EPS estimates by $1.38
• Kraken — NBIX after-hours price near $160
• Closing Look, Monday November 2, 2026 — NBIX up 10.66% after hours

FAQ

Why did Neurocrine stock jump after hours on November 2, 2026?

Neurocrine beat earnings and revenue estimates, grew total revenue 41% to $1.1 billion, and raised full-year Ingrezza sales guidance, sending the shares up about 10% after the close.

How much did Ingrezza sell in the third quarter?

Ingrezza net product sales were $801 million, up 17% year over year, and Neurocrine raised its 2026 Ingrezza guidance to $2.9 billion to $2.925 billion.

What were Neurocrine's Q3 2026 earnings?

The company reported earnings of $3.29 a share on revenue of $1.123 billion, beating the $1.91-a-share consensus estimate, with GAAP net income of $206.5 million.

What should investors watch next for Neurocrine?

Whether the after-hours gain holds in regular trading, fourth-quarter Ingrezza sales against the raised guidance, and 2027 Phase 3 readouts for osavampator and direclidine.